# Healthequity, Inc.: financial statements, quarterly

HQY · Nasdaq · CIK 1428336 · [Industrials](/sectors/industrials.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/hqy.md) · [Financials](/companies/hqy/financials.md) · [Filings](/companies/hqy/filings.md) · [Insiders](/companies/hqy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hqy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [249](/filings/0001428336-24-000110.md) | [262](/filings/0001428336-24-000016.md) | [288](/filings/0001428336-25-000022.md) | [300](/filings/0001428336-25-000029.md) | [300](/filings/0001428336-25-000036.md) | [312 d](/filings/0001428336-26-000010.md) | [331](/filings/0001428336-26-000028.md) | [326](/filings/0001428336-26-000041.md) | [322](/filings/0001428336-25-000036.md) | [335 d](/filings/0001428336-26-000010.md) | [355](/filings/0001428336-26-000028.md) | [351](/filings/0001428336-26-000041.md) |
| Cost of revenue | $m | [90.0](/filings/0001428336-24-000110.md) | [99.1](/filings/0001428336-24-000016.md) | [100](/filings/0001428336-25-000022.md) | [95.9](/filings/0001428336-25-000029.md) | [103](/filings/0001428336-25-000036.md) | [123 d](/filings/0001428336-26-000010.md) | [107](/filings/0001428336-26-000028.md) | [93.2](/filings/0001428336-26-000041.md) | [94.1](/filings/0001428336-25-000036.md) | [106 d](/filings/0001428336-26-000010.md) | [98.3](/filings/0001428336-26-000028.md) | [92.8](/filings/0001428336-26-000041.md) |
| Gross profit | $m | [159](/filings/0001428336-24-000110.md) | [163](/filings/0001428336-24-000016.md) | [187](/filings/0001428336-25-000022.md) | [204](/filings/0001428336-25-000029.md) | [197](/filings/0001428336-25-000036.md) | [189 d](/filings/0001428336-26-000010.md) | [224](/filings/0001428336-26-000028.md) | [233](/filings/0001428336-26-000041.md) | [228](/filings/0001428336-25-000036.md) | [228 d](/filings/0001428336-26-000010.md) | [256](/filings/0001428336-26-000028.md) | [258](/filings/0001428336-26-000041.md) |
| Research and development | $m | [55.6](/filings/0001428336-24-000110.md) | [55.2 d](/filings/0001428336-26-000010.md) | [56.1](/filings/0001428336-25-000022.md) | [58.6](/filings/0001428336-25-000029.md) | [60.2](/filings/0001428336-25-000036.md) | [64.7 d](/filings/0001428336-26-000010.md) | [61.4](/filings/0001428336-26-000028.md) | [64.8](/filings/0001428336-26-000041.md) | [65.9](/filings/0001428336-25-000036.md) | [70.4 d](/filings/0001428336-26-000010.md) | [67.8](/filings/0001428336-26-000028.md) | [73.9](/filings/0001428336-26-000041.md) |
| Operating income | $m | [30.9](/filings/0001428336-24-000110.md) | [38.9 d](/filings/0001428336-26-000010.md) | [41.6](/filings/0001428336-25-000022.md) | [58.9](/filings/0001428336-25-000029.md) | [19.6](/filings/0001428336-25-000036.md) | [42.2 d](/filings/0001428336-26-000010.md) | [83.1](/filings/0001428336-26-000028.md) | [89.6](/filings/0001428336-26-000041.md) | [78.7](/filings/0001428336-25-000036.md) | [71.1 d](/filings/0001428336-26-000010.md) | [103](/filings/0001428336-26-000028.md) | [98.7](/filings/0001428336-26-000041.md) |
| Interest expense | $m | [13.5](/filings/0001428336-23-000037.md) | [13.6 d](/filings/0001428336-24-000016.md) | [11.8](/filings/0001428336-24-000036.md) | [15.4](/filings/0001428336-25-000029.md) | [18.2](/filings/0001428336-25-000036.md) | [15.3 d](/filings/0001428336-26-000010.md) | [14.9](/filings/0001428336-26-000028.md) | [15.0](/filings/0001428336-26-000041.md) | [14.0](/filings/0001428336-25-000036.md) | [13.3 d](/filings/0001428336-26-000010.md) | [12.6](/filings/0001428336-26-000028.md) | [12.6](/filings/0001428336-26-000041.md) |
| Income tax | $m | [6.4](/filings/0001428336-24-000110.md) | [3.4](/filings/0001428336-24-000016.md) | [4.4](/filings/0001428336-25-000022.md) | [10.8](/filings/0001428336-25-000029.md) | [0.5](/filings/0001428336-25-000036.md) | [3.6 d](/filings/0001428336-26-000010.md) | [17.0](/filings/0001428336-26-000028.md) | [18.2](/filings/0001428336-26-000041.md) | [15.8](/filings/0001428336-25-000036.md) | [11.2 d](/filings/0001428336-26-000010.md) | [23.0](/filings/0001428336-26-000028.md) | [22.2](/filings/0001428336-26-000041.md) |
| Net income | $m | [14.7](/filings/0001428336-24-000110.md) | [26.4](/filings/0001428336-24-000016.md) | [28.8](/filings/0001428336-25-000022.md) | [35.8](/filings/0001428336-25-000029.md) | [5.7](/filings/0001428336-25-000036.md) | [26.4 d](/filings/0001428336-26-000010.md) | [53.9](/filings/0001428336-26-000028.md) | [59.9](/filings/0001428336-26-000041.md) | [51.7](/filings/0001428336-25-000036.md) | [49.7 d](/filings/0001428336-26-000010.md) | [69.4](/filings/0001428336-26-000028.md) | [65.6](/filings/0001428336-26-000041.md) |
| Diluted EPS | $ per share | [0.17](/filings/0001428336-24-000110.md) | not reported | [0.33](/filings/0001428336-25-000022.md) | [0.40](/filings/0001428336-25-000029.md) | [0.06](/filings/0001428336-25-000036.md) | not reported | [0.61](/filings/0001428336-26-000028.md) | [0.68](/filings/0001428336-26-000041.md) | [0.59](/filings/0001428336-25-000036.md) | not reported | [0.82](/filings/0001428336-26-000028.md) | [0.78](/filings/0001428336-26-000041.md) |
| Basic EPS | $ per share | [0.17](/filings/0001428336-24-000110.md) | not reported | [0.33](/filings/0001428336-25-000022.md) | [0.41](/filings/0001428336-25-000029.md) | [0.07](/filings/0001428336-25-000036.md) | not reported | [0.62](/filings/0001428336-26-000028.md) | [0.69](/filings/0001428336-26-000041.md) | [0.60](/filings/0001428336-25-000036.md) | not reported | [0.82](/filings/0001428336-26-000028.md) | [0.79](/filings/0001428336-26-000041.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [334](/filings/0001428336-23-000037.md) | [404](/filings/0001428336-25-000009.md) | [251](/filings/0001428336-24-000036.md) | [327](/filings/0001428336-24-000102.md) | [322](/filings/0001428336-24-000110.md) | [296](/filings/0001428336-26-000010.md) | [288](/filings/0001428336-25-000022.md) | [304](/filings/0001428336-25-000029.md) | [309](/filings/0001428336-25-000036.md) | [319](/filings/0001428336-26-000041.md) | [265](/filings/0001428336-26-000028.md) | [256](/filings/0001428336-26-000041.md) |
| Current assets | $m | [474](/filings/0001428336-23-000037.md) | [557](/filings/0001428336-25-000009.md) | [405](/filings/0001428336-24-000036.md) | [496](/filings/0001428336-24-000102.md) | [495](/filings/0001428336-24-000110.md) | [478](/filings/0001428336-26-000010.md) | [473](/filings/0001428336-25-000022.md) | [493](/filings/0001428336-25-000029.md) | [499](/filings/0001428336-25-000036.md) | [512](/filings/0001428336-26-000041.md) | [467](/filings/0001428336-26-000028.md) | [460](/filings/0001428336-26-000041.md) |
| Total assets | $m | [3,094](/filings/0001428336-23-000037.md) | [3,164](/filings/0001428336-25-000009.md) | [3,246](/filings/0001428336-24-000036.md) | [3,514](/filings/0001428336-24-000102.md) | [3,488](/filings/0001428336-24-000110.md) | [3,449](/filings/0001428336-26-000010.md) | [3,416](/filings/0001428336-25-000022.md) | [3,417](/filings/0001428336-25-000029.md) | [3,398](/filings/0001428336-25-000036.md) | [3,380](/filings/0001428336-26-000041.md) | [3,306](/filings/0001428336-26-000028.md) | [3,271](/filings/0001428336-26-000041.md) |
| Current liabilities | $m | [96.2](/filings/0001428336-23-000037.md) | [117](/filings/0001428336-25-000009.md) | [92.2](/filings/0001428336-24-000036.md) | [121](/filings/0001428336-24-000102.md) | [155](/filings/0001428336-24-000110.md) | [156](/filings/0001428336-26-000010.md) | [116](/filings/0001428336-25-000022.md) | [117](/filings/0001428336-25-000029.md) | [121](/filings/0001428336-25-000036.md) | [157](/filings/0001428336-26-000041.md) | [136](/filings/0001428336-26-000028.md) | [154](/filings/0001428336-26-000041.md) |
| Total liabilities | $m | [1,106](/filings/0001428336-23-000037.md) | [1,129](/filings/0001428336-25-000009.md) | [1,149](/filings/0001428336-24-000036.md) | [1,357](/filings/0001428336-24-000102.md) | [1,364](/filings/0001428336-24-000110.md) | [1,334](/filings/0001428336-26-000010.md) | [1,292](/filings/0001428336-25-000022.md) | [1,270](/filings/0001428336-25-000029.md) | [1,264](/filings/0001428336-25-000036.md) | [1,273](/filings/0001428336-26-000041.md) | [1,259](/filings/0001428336-26-000028.md) | [1,281](/filings/0001428336-26-000041.md) |
| Long-term debt | $m | [874](/filings/0001428336-23-000037.md) | [875](/filings/0001428336-25-000009.md) | [926](/filings/0001428336-24-000036.md) | [1,101](/filings/0001428336-24-000102.md) | [1,081](/filings/0001428336-24-000110.md) | [1,056](/filings/0001428336-26-000010.md) | [1,057](/filings/0001428336-25-000022.md) | [1,007](/filings/0001428336-25-000029.md) | [982](/filings/0001428336-25-000036.md) | [957](/filings/0001428336-26-000041.md) | [943](/filings/0001428336-26-000028.md) | [931](/filings/0001428336-26-000041.md) |
| Current portion of debt | $m | [0.0](/filings/0001428336-23-000037.md) | [0.0](/filings/0001428336-25-000009.md) | [0.0](/filings/0001428336-24-000036.md) | [0.0](/filings/0001428336-24-000102.md) | [0.0](/filings/0001428336-24-000110.md) | [0.0](/filings/0001428336-26-000010.md) | [0.0](/filings/0001428336-25-000022.md) | [0.0](/filings/0001428336-25-000029.md) | [0.0](/filings/0001428336-25-000036.md) | [0.0](/filings/0001428336-26-000041.md) | [0.0](/filings/0001428336-26-000028.md) | [0.0](/filings/0001428336-26-000041.md) |
| Shareholders' equity | $m | [1,988](/filings/0001428336-24-000110.md) | [2,035](/filings/0001428336-26-000010.md) | [2,098](/filings/0001428336-25-000029.md) | [2,157](/filings/0001428336-25-000036.md) | [2,125](/filings/0001428336-25-000036.md) | [2,115](/filings/0001428336-26-000041.md) | [2,124](/filings/0001428336-26-000041.md) | [2,146](/filings/0001428336-26-000041.md) | [2,134](/filings/0001428336-25-000036.md) | [2,107](/filings/0001428336-26-000041.md) | [2,047](/filings/0001428336-26-000041.md) | [1,990](/filings/0001428336-26-000041.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [57.1 d](/filings/0001428336-24-000110.md) | [77.1 d](/filings/0001428336-26-000010.md) | [65.4](/filings/0001428336-25-000022.md) | [108 d](/filings/0001428336-25-000029.md) | [90.6 d](/filings/0001428336-25-000036.md) | [75.7 d](/filings/0001428336-26-000010.md) | [64.7](/filings/0001428336-26-000028.md) | [136 d](/filings/0001428336-26-000041.md) | [139 d](/filings/0001428336-25-000036.md) | [118 d](/filings/0001428336-26-000010.md) | [97.5](/filings/0001428336-26-000028.md) | [136 d](/filings/0001428336-26-000041.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001428336-24-000110.md) | [0.6 d](/filings/0001428336-26-000010.md) | [0.7](/filings/0001428336-25-000022.md) | [0.7 d](/filings/0001428336-25-000029.md) | [0.3 d](/filings/0001428336-25-000036.md) | [0.3 d](/filings/0001428336-26-000010.md) | [0.1](/filings/0001428336-26-000028.md) | [0.8 d](/filings/0001428336-26-000041.md) | [0.8 d](/filings/0001428336-25-000036.md) | [0.3 d](/filings/0001428336-26-000010.md) | [0.4](/filings/0001428336-26-000028.md) | [1.0 d](/filings/0001428336-26-000041.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001428336-26-000010.md) | [0.0](/filings/0001428336-25-000022.md) | [0.0 d](/filings/0001428336-25-000029.md) | [58.5 d](/filings/0001428336-25-000036.md) | [63.0 d](/filings/0001428336-26-000010.md) | [59.1](/filings/0001428336-26-000028.md) | [66.7 d](/filings/0001428336-26-000041.md) | [92.4 d](/filings/0001428336-25-000036.md) | [81.0 d](/filings/0001428336-26-000010.md) | [123](/filings/0001428336-26-000028.md) | [108 d](/filings/0001428336-26-000041.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [84.6](/filings/0001428336-23-000037.md) | [86.1](/filings/0001428336-24-000036.md) | [86.3](/filings/0001428336-24-000102.md) | [87.1](/filings/0001428336-24-000110.md) | [88.3](/filings/0001428336-25-000022.md) | [88.6](/filings/0001428336-25-000029.md) | [88.6](/filings/0001428336-25-000036.md) | [88.4](/filings/0001428336-26-000028.md) | [87.7](/filings/0001428336-26-000041.md) | [87.0](/filings/0001428336-25-000036.md) | [85.0](/filings/0001428336-26-000028.md) | [84.0](/filings/0001428336-26-000041.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 82,715,296 at 2026-08-20, from the cover of the [10-Q filed 2026-08-27](/filings/0001428336-26-000041.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.